Description
GOVERNMENT'S NOTICE THAT IT WILL NOT EXERCISE 2ND OPTION YEAR FOR AMITRIPTYLINE HCL TABLETS CONTRACT 36E79721D0010 WITH SANDOZ INC. CONTRACT WILL EXPIRE ON 03/06/2023 AT THE END OF OPTION YEAR ONE.
Base award description: AWARD FOR AMITRIPTYLINE HCL TABLETS FOR THE BASE YEAR WITH FOUR ONE YEAR OPTIONS. EFFECTIVE 3/7/2021 - 3/6/2022.
Modification chain · 5 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2020-12-21+$0= $0
- Mod P000012022-01-05+$0= $0
- Mod P000022022-02-04+$0= $0
- Mod P000032022-12-20+$0= $0
- Mod P000042023-01-12+$0= $0
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2020-12-21 | +$0 | $0 | AWARD FOR AMITRIPTYLINE HCL TABLETS FOR THE BASE YEAR WITH FOUR ONE YEAR OPTIONS. EFFECTIVE 3/7/2021 - 3/6/202… |
| Mod P00001· ADD SUBCONTRACTING PLAN | 2022-01-05 | +$0 | $0 | UPDATE CONTRACT 36E79721D0010 SUBCONTRACTING PLAN FROM 01/01/2022 - 12/31/2022. |
| Mod P00002· EXERCISE AN OPTION | 2022-02-04 | +$0 | $0 | EXERCISE OF OPTION YEAR ONE FOR CONTRACT 36E79721D0010 FOR AMITRIPTYLINE HCL TABLETS WITH NO PRICE CHANGES TO… |
| Mod P00003· ADD SUBCONTRACTING PLAN | 2022-12-20 | +$0 | $0 | UPDATE CONTRACT 36E79721D0010 SUBCONTRACTING PLAN FROM 01/01/2023 - 12/31/2023. |
| Mod P00004· OTHER ADMINISTRATIVE ACTION | 2023-01-12 | +$0 | $0 | GOVERNMENT'S NOTICE THAT IT WILL NOT EXERCISE 2ND OPTION YEAR FOR AMITRIPTYLINE HCL TABLETS CONTRACT 36E79721D… |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI ETJGHMFH1MT5)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36F79723D0187 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36E79723D0005 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36E79723D0001 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36E79722D0033 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2022 |
| 36E79722D0016 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2022 |
| 36E79722D0011 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2022 |
Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36E79726A0025 | CHIESI USA INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0024 | NEUROTECH PHARMACEUTICALS, INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0023 | TAKEDA PHARMACEUTICALS AMERICA, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726D0041 | GOLDEN STATE MEDICAL SUPPLY, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0022 | AURINIA PHARMA US INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79721D0010_3600 · retrieved 2026-09-26.